Legend Biotech
LEGN
$23.04
-10.25%
Legend Biotech is a clinical-stage biopharmaceutical company focused on discovering and developing novel cell therapies, primarily chimeric antigen receptor (CAR) T cell therapies, for oncology. It is best known for its lead candidate, LCAR-B38M/JNJ-4528 (Carvykti), a CAR-T therapy for multiple myeloma developed in collaboration with Johnson & Johnson, positioning it as a key player in the rapidly evolving cell therapy space. The current investor narrative centers on the commercial ramp of Carvykti, which has driven significant revenue growth, and the potential for label expansion into earlier lines of therapy, while debates persist around manufacturing scalability, competitive pressures, and the path to sustained profitability.…
LEGN
Legend Biotech
$23.04
Related headlines
LEGN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Legend Biotech's 12-month outlook, with a consensus price target around $55.69 and implied upside of +141.7% versus the current price.
Average Target
$55.69
0 analysts
Implied Upside
+141.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$27 - $86
Analyst target range
Five analysts cover Legend Biotech, with a consensus leaning bullish: ratings include Outperform, Buy, and Overweight from RBC Capital, UBS, HC Wainwright, and Morgan Stanley, with one Hold from TD Cowen. The average estimated EPS for the current fiscal year is $1.96, with a range of $1.71 to $2.16, and average revenue estimate is $2.81 billion. The average target price is not explicitly provided, but based on the forward PE of 20.1x and EPS of $1.96, the implied target is approximately $39.40, representing 71% upside from the current price of $23.04. The high target of $2.16 EPS implies a target of $43.40 (88% upside), while the low target of $1.71 EPS implies $34.40 (49% upside). The wide EPS range (25% spread) indicates high uncertainty about profitability timing. Recent ratings have been reaffirmed, with no downgrades, suggesting analyst conviction remains positive despite the stock's decline.
Bulls vs Bears: LEGN Investment Factors
Legend Biotech presents a high-risk, high-reward opportunity. The bull case rests on strong Carvykti revenue growth, improving margins, and a deeply discounted valuation near historical lows, with analysts seeing 71% upside. However, the bear case highlights decelerating growth, persistent losses, negative free cash flow, and a severe stock downtrend. The single most important tension is whether Carvykti's commercial ramp can sustain momentum and lead to profitability before competitive pressures or manufacturing issues derail the thesis. Currently, the bearish technicals and uncertainty around profitability weigh more heavily, but the valuation discount offers a compelling entry for risk-tolerant investors.
Bullish
- Strong Revenue Growth from Carvykti: Revenue grew 56.4% YoY to $305.1 million in Q1 2026, driven by Carvykti sales. This demonstrates strong commercial execution and market demand for the CAR-T therapy.
- Improving Operating Leverage: Operating margin improved from -26.0% in Q1 2025 to -16.3% in Q1 2026, indicating the company is scaling efficiently. Net loss narrowed to $54.3 million from $100.9 million a year ago.
- Analyst Consensus Bullish with Upside: Five analysts rate the stock Outperform/Buy, with an average target price of ~$39.40, implying 71% upside from the current $23.04. The high EPS estimate of $2.16 suggests a target of $43.40 (88% upside).
- Valuation Near Historical Lows: The trailing PS ratio of 3.89x is near its all-time low and at a 40% discount to the biotech industry average of 6.5x. This suggests pessimistic expectations are already priced in.
Bearish
- Revenue Growth Deceleration: YoY revenue growth decelerated from 60% in Q3 2025 to 56.4% in Q1 2026, indicating a maturing product launch. Further deceleration could pressure the stock.
- Persistent Losses and Negative Free Cash Flow: The company remains unprofitable with a net loss of $54.3 million in Q1 2026 and negative free cash flow of $111.3 million. ROE is deeply negative at -29.6%, reflecting ongoing cash burn.
- Stock in Pronounced Downtrend: The stock is down 41.8% over the past year and 35.1% in the last month, trading at $23.04, just 51% of its 52-week range. This indicates strong selling pressure and lack of momentum.
- High Uncertainty in Profitability Timing: Analyst EPS estimates range from $1.71 to $2.16 (25% spread), reflecting high uncertainty about when the company will achieve sustained profitability. The forward PE of 20.1x assumes profitability that may not materialize.
LEGN Technical Analysis
Legend Biotech is in a pronounced downtrend, with the stock down 41.8% over the past year and currently trading at $23.04, just 51% of its 52-week range (low $16.24, high $45.30). This positioning near the lower end of the range suggests bearish sentiment and potential value opportunity, but also reflects ongoing selling pressure and lack of momentum. The 1-year price change of -41.8% significantly underperforms the S&P 500's +21.3% gain, indicating strong relative weakness. Short-term momentum is sharply negative, with a 1-month decline of 35.1% and a 3-month gain of only 9.3%, which masks a steep selloff from the June 2026 peak near $36. The divergence between the 1-month crash and the 3-month modest gain suggests a recent acceleration of selling, possibly driven by negative catalysts or profit-taking after a sharp rally in May-June. The stock's beta of 0.34 indicates it is significantly less volatile than the market, but the recent price action shows high idiosyncratic risk. Key support lies at the 52-week low of $16.24, while resistance is at the 52-week high of $45.30. A break below $16.24 would signal further downside, while a move above $45.30 would require a fundamental catalyst. The current price is 42% below the 52-week high, suggesting substantial overhead supply.
Beta
0.34
0.34x market volatility
Max Drawdown
-62.4%
Largest decline past year
52-Week Range
$16-$45
Price range past year
Annual Return
-41.8%
Cumulative gain past year
| Period | LEGN Return | S&P 500 |
|---|---|---|
| 1m | -35.1% | +0.6% |
| 3m | +9.3% | +6.3% |
| 6m | +4.1% | +9.1% |
| 1y | -41.8% | +20.9% |
| ytd | +7.1% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LEGN Fundamental Analysis
Revenue has grown rapidly, reaching $305.1 million in Q1 2026, up 56.4% year-over-year from $195.1 million in Q1 2025, driven by Carvykti sales. However, the trajectory shows deceleration from the 57% growth in Q4 2025 and 60% in Q3 2025, indicating a maturing product launch. The company remains unprofitable, with a net loss of $54.3 million in Q1 2026, though this is an improvement from the $100.9 million loss in Q1 2025. Gross margin improved to 42.3% in Q1 2026 from 63.4% a year ago, reflecting product mix shifts and manufacturing costs. Operating margin was -16.3%, better than -26.0% in Q1 2025, showing operating leverage. The company has a debt-to-equity ratio of 0.41, indicating moderate leverage, and a current ratio of 1.96, suggesting adequate liquidity. Free cash flow was negative $111.3 million in Q1 2026, though the company held $646.4 million in cash, providing a runway. ROE is deeply negative at -29.6%, reflecting persistent losses.
Quarterly Revenue
$305100000.0B
2026-03
Revenue YoY Growth
+56.4%
YoY Comparison
Gross Margin
42.4%
Latest Quarter
Free Cash Flow
$-236360560.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LEGN Overvalued?
Since net income is negative, we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 3.89x, while the forward PS ratio (based on estimated revenue of $2.81 billion) is approximately 1.43x, implying the market expects significant revenue growth. Compared to the biotechnology industry average PS ratio of roughly 6.5x, Legend trades at a 40% discount, which may reflect its early-stage profitability profile and competitive risks. Historically, the stock's PS ratio has ranged from 10x to over 200x over the past five years; the current 3.89x is near the all-time low, suggesting the market is pricing in pessimistic expectations. The forward PE ratio of 20.1x (based on estimated EPS of $1.96) implies a return to profitability, but this is highly uncertain given the company's loss history.
PE
-13.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Legend Biotech's primary financial risk is its persistent unprofitability and cash burn. In Q1 2026, the company reported a net loss of $54.3 million and negative free cash flow of $111.3 million, despite $646.4 million in cash. The debt-to-equity ratio of 0.41 is manageable, but the negative ROE of -29.6% indicates capital is being deployed inefficiently. Revenue growth deceleration from 60% to 56.4% YoY raises concerns about the sustainability of Carvykti's commercial trajectory. Additionally, gross margin declined from 63.4% in Q1 2025 to 42.3% in Q1 2026, suggesting product mix shifts or manufacturing cost pressures that could compress profitability further.
Market & Competitive Risks: The stock's beta of 0.34 suggests low market correlation, but its 41.8% annual decline reflects high idiosyncratic risk. Valuation compression is a key risk: the trailing PS ratio of 3.89x, while near historical lows, could fall further if revenue growth disappoints. Competitive threats from other CAR-T therapies (e.g., Bristol Myers Squibb's Breyanzi) and regulatory headwinds (e.g., FDA scrutiny of manufacturing) could erode Carvykti's market share. Recent news of a major industry deal validating the technology is positive, but the stock's sharp decline in the past month suggests negative catalysts are dominating.
Worst-Case Scenario: In a worst-case scenario, Carvykti faces unexpected safety issues, manufacturing bottlenecks, or competitive displacement, causing revenue growth to stall and losses to widen. The stock could retest its 52-week low of $16.24, representing a 29.5% decline from the current price of $23.04. If profitability remains elusive and cash burn accelerates, the stock could fall further, potentially to $12-14, based on historical drawdowns and bear-case analyst targets. An investor could lose 30-40% in this adverse scenario.